Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

This study has been terminated.
(low accrual)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Bruno C. Medeiros, Stanford University
ClinicalTrials.gov Identifier:
NCT01401322
First received: July 20, 2011
Last updated: July 26, 2012
Last verified: July 2012

July 20, 2011
July 26, 2012
January 2011
January 2012   (final data collection date for primary outcome measure)
  • Progression-Free Survival (PFS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Overall Survival (OS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01401322 on ClinicalTrials.gov Archive Site
Tumor Response (TR) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Primary Objective:

• Determine the complete response (CR) rate, duration of remission of single agent lenalidomide in patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL), after at least one previous treatment regimen.

Secondary Objective:

• Establish the toxicity profile for lenalidomide in this patient population

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Adult Acute Lymphocytic Leukemia
Drug: lenalidomide
50 mg; po
Other Name: Revlimid
Experimental: lenalidomide
Intervention: Drug: lenalidomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
May 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

To be eligible to participate in this study, a patient must meet the following criteria:

  • WHO-confirmed Acute lymphoblastic leukemia with > 10% bone marrow or peripheral blood blasts; failed to achieve CR or relapse after prior therapy.
  • Untreated patients > 60, if not candidates for standard induction, will also be eligible to participate.
  • Age >= 18 and not a candidate for alternative, curative treatment regimens
  • Unwilling or unable to receive conventional chemotherapy (any age)
  • ECOG performance status <= 2 (See Appendix B for definitions)
  • Life expectancy > 2 months
  • All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL 10 - 14 days prior to study enrollment and again within 24 hours prior to prescribing lenalidomide cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. (See Appendix A: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods).
  • Willing and able to understand and voluntarily sign a written informed consent
  • Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from this study:

  • Prior therapy with lenalidomide
  • History of intolerance to thalidomide or development of erythema nodosum while taking thalidomide or similar drugs
  • Patients with advanced malignant hepatic tumors.
  • Concomitant treatment with other anti-neoplastic agents, with the exception of hydroxyurea
  • Anti-neoplastic treatment less than four weeks prior to enrollment, with the exception of hydroxyurea
  • Use of any other experimental drug or therapy within 14 days of baseline
  • Inability to swallow or absorb drug
  • Active opportunistic infection or treatment for opportunistic infection within four weeks of first day of study drug dosing
  • New York Heart Association Class III or IV heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmias with rapid ventricular response (defined as heart rate greater than 100 beats/minute)
  • Uncontrolled psychiatric illness that would limit compliance with requirementsKnown HIV infection, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Patients who are seropositive because of hepatitis B virus vaccine are eligible
  • Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide
  • Other medical or psychiatric illness or organ dysfunction or laboratory abnormality which in the opinion of the investigator would compromise the patient's safety or interfere with data interpretation
  • Laboratory abnormalities:

    • Either creatinine >=1.5 mg/dL or creatinine clearance <=60 mL/min.
    • Total bilirubin > 1.5 x institutional ULN (unless documented Gilbert's syndrome)
    • AST and ALT > 3 x institutional ULN
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01401322
HEMALL0006, SU-01142011-7364, RV_ALL_PI_0616
Yes
Bruno C. Medeiros, Stanford University
Stanford University
Celgene Corporation
Principal Investigator: Bruno Carneiro de Medeiros Stanford University
Stanford University
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP